Recreational cannabis legalization did not increase prescription stimulant distribution
States with recreational cannabis sales did not see a more pronounced rise in Schedule II stimulant prescriptions compared to states without legal cannabis, despite overall national increases.
Quick Facts
What This Study Found
While total stimulant distribution rates were higher in states with recreational cannabis sales after implementation (p=0.049), there was no significant interaction between time and cannabis sales status (p=0.406), meaning legalization did not contribute to a more pronounced rise in stimulant distribution.
Key Numbers
States with RC had higher post-implementation stimulant rates (p=0.049) but not pre-implementation (p=0.221). Time effect was significant (p<0.05), state effect significant (p=0.045), but time x RC interaction was not (p=0.406).
How They Did This
Researchers compared three-year population-corrected slopes of Schedule II stimulant (amphetamine, lisdexamfetamine, methylphenidate) distribution from the DEA ARCOS database before and after recreational cannabis sales in states with and without legal sales.
Why This Research Matters
Because ADHD-like cognitive deficits can resemble effects of chronic cannabis use, some hypothesized that cannabis legalization might drive increased stimulant prescriptions. This study found no evidence supporting that concern.
The Bigger Picture
Rising stimulant prescriptions are a national trend driven by factors unrelated to cannabis policy. This study adds to evidence that recreational cannabis legalization has not produced many of the feared downstream effects on other substance use or prescribing patterns.
What This Study Doesn't Tell Us
Ecological study design cannot track individual-level associations. ARCOS data measures distribution, not individual prescriptions. Cannot account for illicit cannabis use in non-legal states. Limited follow-up period after legalization.
Questions This Raises
- ?What is driving the national increase in stimulant prescriptions?
- ?Could cannabis legalization affect non-stimulant ADHD medication use or ADHD diagnosis rates?
Trust & Context
- Key Stat:
- No significant interaction (p=0.406)
- Evidence Grade:
- Ecological analysis of national DEA data with appropriate statistical modeling, but cannot track individual-level effects.
- Study Age:
- 2024 analysis of DEA ARCOS distribution data
- Original Title:
- Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA.
- Published In:
- Pharmacopsychiatry, 57(5), 249-254 (2024)
- Authors:
- Alexander, Garrett D(2), Cavanah, Luke R(2), Goldhirsh, Jessica L(2), Huey, Leighton Y, Piper, Brian J
- Database ID:
- RTHC-05074
Evidence Hierarchy
Frequently Asked Questions
Why would cannabis legalization affect ADHD medication?
Some research suggests chronic cannabis use produces cognitive deficits similar to ADHD symptoms, raising the question of whether more cannabis availability could lead to more ADHD diagnoses and stimulant prescriptions.
Are stimulant prescriptions rising nationally?
Yes. The study found significant increases in Schedule II stimulant distribution over time across all states, regardless of cannabis legalization status.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-05074APA
Alexander, Garrett D; Cavanah, Luke R; Goldhirsh, Jessica L; Huey, Leighton Y; Piper, Brian J. (2024). Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA.. Pharmacopsychiatry, 57(5), 249-254. https://doi.org/10.1055/a-2334-6253
MLA
Alexander, Garrett D, et al. "Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA.." Pharmacopsychiatry, 2024. https://doi.org/10.1055/a-2334-6253
RethinkTHC
RethinkTHC Research Database. "Recreational Cannabis Legalization: No Contribution to Risin..." RTHC-05074. Retrieved from https://rethinkthc.com/research/alexander-2024-recreational-cannabis-legalization-no
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.